Pricing

Dianthus Therapeutics Inc (DNTH)

followers ยท
Sector: HEALTH CARE
Industry: BIOTECHNOLOGY & LIFE SCIENCES
SIC: PHARMACEUTICAL PREPARATIONS
CEO: Jason Gardner
Employees: 80
Web site: magentatx.com
7 TIMES SQUARE, 43RD FLOOR, NEW YORK, NY, 10036
929-999-4055
Stock Split History
Date Ratio
2023-09-12 1:16
All 13F Filers Prior Change Hedge Funds 1 Prior Change
Magenta Therapeutics develops medicines to bring the curative power of stem cell transplants to patients with blood cancers, genetic diseases, and autoimmune diseases. It develops MGTA-117, an anti-CD117 antibody that targets hematopoietic stem cells and genetically mutated stem cells that cause acute myeloid leukemia and myelodysplastic syndromes. The company also has a cell therapy program, E478, which is a small molecule aryl hydrocarbon receptor antagonist for stem cell-based gene therapy.
Please log in first to see chart
InvestorHistoryShares Held or Principal AmtMarket Value% of PortfolioPrevious % of PortfolioRankChange in Shares% Change in Shares% OwnershipQtr 1st OwnedEst. Avg PriceSourceSource DateDate Reported
No data available